MacroGenics Stock Price, News & Analysis (NASDAQ:MGNX)

$22.99 -0.21 (-0.91 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$22.99
Today's Range$22.95 - $23.89
52-Week Range$14.36 - $24.26
Volume192,750 shs
Average Volume235,565 shs
Market Capitalization$846.55 million
P/E Ratio-5.12
Dividend YieldN/A
Beta2.79

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MGNX
CUSIPN/A
Phone+1-301-2515172

Debt

Debt-to-Equity RatioN/A
Current Ratio6.46%
Quick Ratio6.46%

Price-To-Earnings

Trailing P/E Ratio-5.12026726057906
Forward P/E Ratio-32.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$91.88 million
Price / Sales9.21
Cash FlowN/A
Price / CashN/A
Book Value$7.71 per share
Price / Book2.98

Profitability

Trailing EPS($4.49)
Net Income$-58,520,000.00
Net Margins-1,526.55%
Return on Equity-69.31%
Return on Assets-58.09%

Miscellaneous

Employees318
Outstanding Shares36,820,000

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) posted its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.09) by $0.19. The biopharmaceutical company earned $1.70 million during the quarter, compared to analysts' expectations of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The firm's revenue for the quarter was down 48.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.97) earnings per share. View MacroGenics' Earnings History.

When will MacroGenics make its next earnings announcement?

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for MacroGenics.

Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2018?

11 brokers have issued 1 year price targets for MacroGenics' shares. Their predictions range from $21.00 to $44.00. On average, they anticipate MacroGenics' stock price to reach $31.89 in the next year. View Analyst Ratings for MacroGenics.

What are Wall Street analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:

  • 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (2/13/2018)
  • 2. BTIG Research analysts commented, "Based upon the 4Q16 earnings call hosted last week and our follow-up conversation with management, we present an outline of expected activities during 2017. The majority of the MGNX portfolio will be entering or expanding Phase 1 studies during 2017, which will weigh potential clinical catalysts towards 2H2017 and early 2018. The most significant identified clinical read-out during 2017 will likely be the futility analysis from the Margetuximab pivotal study. We reiterate our Buy Rating but lower our Price Target to $28 from $35 as we push out Margetuximab sales expectations until 2021. A summary of events for 2017 is charted on Page 2 of this report." (3/6/2017)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:

  • Paulo F. Costa, Independent Chairman of the Board (Age 66)
  • Scott Koenig M.D., Ph.D., President, Chief Executive Officer, Director (Age 64)
  • James Karrels MBA, Chief Financial Officer, Senior Vice President, Secretary (Age 50)
  • Ezio Bonvini M.D., Senior Vice President - Research, Chief Scientific Officer (Age 63)
  • Atul Saran, Senior Vice President, General Counsel (Age 43)
  • Eric Risser, Senior Vice President - Business Development and Portfolio Management and Chief Business Officer (Age 44)
  • Thomas Spitznagel Ph.D., Senior Vice President - Bio Pharmaceutical Development and Manufacturing (Age 50)
  • Jon Wigginton, Senior Vice President - Clinical Development and Chief Medical Officer (Age 55)
  • Lynn Cilinski, Vice President, Controller, Treasurer (Age 59)
  • Jay P. Siegel M.D., Director

Who owns MacroGenics stock?

MacroGenics' stock is owned by many different of institutional and retail investors. Top institutional investors include OppenheimerFunds Inc. (10.68%), BlackRock Inc. (7.21%), Wasatch Advisors Inc. (2.79%), Pinnacle Associates Ltd. (2.22%), Hood River Capital Management LLC (1.72%) and Prosight Management LP (1.65%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jon Marc Wigginton, Lynn Cilinski and Paulo F Costa. View Institutional Ownership Trends for MacroGenics.

Who sold MacroGenics stock? Who is selling MacroGenics stock?

MacroGenics' stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Artal Group S.A., Sphera Funds Management LTD., BlackRock Inc., Spark Investment Management LLC, Citadel Advisors LLC, Pinnacle Associates Ltd. and Franklin Resources Inc.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser and Jon Marc Wigginton. View Insider Buying and Selling for MacroGenics.

Who bought MacroGenics stock? Who is buying MacroGenics stock?

MacroGenics' stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Millennium Management LLC, OppenheimerFunds Inc., Renaissance Technologies LLC, Deutsche Bank AG, Candriam Luxembourg S.C.A., Hood River Capital Management LLC and Virtus Fund Advisers LLC. View Insider Buying and Selling for MacroGenics.

How do I buy MacroGenics stock?

Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MacroGenics stock can currently be purchased for approximately $22.99.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $846.55 million and generates $91.88 million in revenue each year. The biopharmaceutical company earns $-58,520,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. MacroGenics employs 318 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 Medical Center Dr, ROCKVILLE, MD 20850-3343, United States. The biopharmaceutical company can be reached via phone at +1-301-2515172.


MarketBeat Community Rating for MacroGenics (MGNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MacroGenics (NASDAQ:MGNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.822.822.82
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.89$31.33$31.33$33.78
Price Target Upside: 37.27% upside67.47% upside71.69% upside95.47% upside

MacroGenics (NASDAQ:MGNX) Consensus Price Target History

Price Target History for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018CowenReiterated RatingBuyLowView Rating Details
1/23/2018SunTrust BanksReiterated RatingBuy$31.00HighView Rating Details
1/23/2018BTIG ResearchReiterated RatingBuy$28.00HighView Rating Details
12/11/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
11/10/2017CitigroupBoost Price TargetNeutral$18.00 -> $22.00N/AView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$34.00HighView Rating Details
9/11/2017WedbushReiterated RatingOutperform$44.00HighView Rating Details
8/7/2017Morgan StanleyLower Price TargetEqual Weight$22.00 -> $21.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
6/14/2016OppenheimerReiterated RatingBuyN/AView Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

MacroGenics (NASDAQ:MGNX) Earnings History and Estimates Chart

Earnings by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ MGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$2.62N/AView Earnings Details
11/8/2017Q3 2017($1.09)($1.28)$5.50 million$1.70 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.05)($1.14)$15.82 million$1.70 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.56)($0.89)$12.36 million$8.18 millionViewN/AView Earnings Details
11/4/2015Q3 2015($0.21)($0.46)$22.95 million$14.68 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01$19.67 million$20.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MacroGenics (NASDAQ:MGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($4.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.10)($0.97)($1.04)
Q2 20182($1.13)($0.88)($1.01)
Q3 20182($1.15)($0.91)($1.03)
Q4 20182($1.18)($0.93)($1.06)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for MacroGenics (NASDAQ:MGNX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MacroGenics (NASDAQ MGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 85.30%
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ MGNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/24/2018Eric Blasius RisserSVPSell3,000$22.50$67,500.0012,100View SEC Filing  
1/17/2018Jon Marc WiggintonSVPSell5,000$20.00$100,000.00View SEC Filing  
11/21/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.0035,000View SEC Filing  
10/25/2017Jon Marc WiggintonSVPSell10,000$20.00$200,000.0040,000View SEC Filing  
6/5/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.0035,000View SEC Filing  
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.0045,000View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.0010,000View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.688,154View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.0020,000View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.005,000View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.8410,845View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.006,923View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.0059,435View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.001,923View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.4870,317View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.9373,434View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MacroGenics (NASDAQ MGNX) News Headlines

Source:
DateHeadline
BidaskClub Upgrades MacroGenics (MGNX) to "Hold"BidaskClub Upgrades MacroGenics (MGNX) to "Hold"
www.americanbankingnews.com - February 19 at 4:02 PM
MacroGenics (MGNX) to Release Earnings on MondayMacroGenics (MGNX) to Release Earnings on Monday
www.americanbankingnews.com - February 19 at 5:22 AM
MacroGenics (MGNX) Lifted to Hold at Zacks Investment ResearchMacroGenics (MGNX) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - February 19 at 12:02 AM
MacroGenics (MGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowMacroGenics (MGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:43 PM
MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference CallMacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call
finance.yahoo.com - February 15 at 6:37 AM
MacroGenics Inc (MGNX) Receives Average Recommendation of "Hold" from BrokeragesMacroGenics Inc (MGNX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 9 at 3:40 PM
Zacks: Analysts Expect MacroGenics Inc (MGNX) Will Announce Earnings of $2.58 Per ShareZacks: Analysts Expect MacroGenics Inc (MGNX) Will Announce Earnings of $2.58 Per Share
www.americanbankingnews.com - February 8 at 7:18 PM
MacroGenics (MGNX) Lowered to "Sell" at Zacks Investment ResearchMacroGenics (MGNX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 6:20 AM
BidaskClub Upgrades MacroGenics (MGNX) to "Sell"BidaskClub Upgrades MacroGenics (MGNX) to "Sell"
www.americanbankingnews.com - January 28 at 7:52 AM
SunTrust Banks Research Analysts Reduce Earnings Estimates for MacroGenics Inc (MGNX)SunTrust Banks Research Analysts Reduce Earnings Estimates for MacroGenics Inc (MGNX)
www.americanbankingnews.com - January 26 at 2:08 PM
Eric Blasius Risser Sells 3,000 Shares of MacroGenics Inc (MGNX) StockEric Blasius Risser Sells 3,000 Shares of MacroGenics Inc (MGNX) Stock
www.americanbankingnews.com - January 25 at 9:44 PM
MacroGenics (MGNX) Receives "Buy" Rating from CowenMacroGenics (MGNX) Receives "Buy" Rating from Cowen
www.americanbankingnews.com - January 24 at 8:34 PM
Macrogenics (MGNX) to Continue SOPHIA Study of Margetuximab Based on Completion of Interim Futility AnalysisMacrogenics (MGNX) to Continue SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
www.streetinsider.com - January 24 at 3:28 PM
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility AnalysisMacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
finance.yahoo.com - January 24 at 9:52 AM
BTIG Research Reiterates "Buy" Rating for MacroGenics (MGNX)BTIG Research Reiterates "Buy" Rating for MacroGenics (MGNX)
www.americanbankingnews.com - January 23 at 7:32 AM
MacroGenics Inc Forecasted to Earn FY2022 Earnings of $9.69 Per Share (MGNX)MacroGenics Inc Forecasted to Earn FY2022 Earnings of $9.69 Per Share (MGNX)
www.americanbankingnews.com - January 22 at 3:22 PM
MacroGenics Inc Forecasted to Earn FY2022 Earnings of ($1.39) Per Share (MGNX)MacroGenics Inc Forecasted to Earn FY2022 Earnings of ($1.39) Per Share (MGNX)
www.americanbankingnews.com - January 22 at 3:22 PM
Macrogenics (MGNX) Says Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at ASCO Gastrointestinal Cancers SymposiumMacrogenics (MGNX) Says Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at ASCO Gastrointestinal Cancers Symposium
www.streetinsider.com - January 19 at 6:11 PM
MacroGenics Inc (MGNX) SVP Sells $100,000.00 in StockMacroGenics Inc (MGNX) SVP Sells $100,000.00 in Stock
www.americanbankingnews.com - January 18 at 7:58 PM
Macrogenics (MGNX) Says Phase 1b/2 Study of Margetuximab in ... - StreetInsider.comMacrogenics (MGNX) Says Phase 1b/2 Study of Margetuximab in ... - StreetInsider.com
www.streetinsider.com - January 18 at 5:13 PM
Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers SymposiumPhase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium
finance.yahoo.com - January 18 at 5:13 PM
MacroGenics Inc (MGNX) Receives Consensus Rating of "Buy" from BrokeragesMacroGenics Inc (MGNX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 15 at 4:10 PM
MacroGenics (MGNX) Downgraded by BidaskClubMacroGenics (MGNX) Downgraded by BidaskClub
www.americanbankingnews.com - January 14 at 11:10 PM
Financial Review: MacroGenics (MGNX) and Atara Biotherapeutics (ATRA)Financial Review: MacroGenics (MGNX) and Atara Biotherapeutics (ATRA)
www.americanbankingnews.com - January 11 at 11:48 AM
Incyte’s Collaborations and Developments in 4Q17Incyte’s Collaborations and Developments in 4Q17
finance.yahoo.com - January 10 at 9:18 AM
Zacks: Analysts Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $152.60 MillionZacks: Analysts Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $152.60 Million
www.americanbankingnews.com - January 7 at 4:42 AM
MacroGenics (MGNX) Upgraded to Sell by BidaskClubMacroGenics (MGNX) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - January 6 at 12:20 AM
MacroGenics Inc (MGNX) Expected to Post Earnings of $2.58 Per ShareMacroGenics Inc (MGNX) Expected to Post Earnings of $2.58 Per Share
www.americanbankingnews.com - January 5 at 5:32 PM
MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 5:35 PM
MacroGenics, Inc. (MGNX)MacroGenics, Inc. (MGNX)
finance.yahoo.com - January 4 at 9:12 AM
MacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific MoleculeMacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule
finance.yahoo.com - January 4 at 9:12 AM
MacroGenics (MGNX) Lowered to Sell at Zacks Investment ResearchMacroGenics (MGNX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 3 at 11:54 AM
ETFs with exposure to MacroGenics, Inc. : December 27, 2017ETFs with exposure to MacroGenics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 5:10 PM
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 3:34 PM
$152.60 Million in Sales Expected for MacroGenics Inc (MGNX) This Quarter$152.60 Million in Sales Expected for MacroGenics Inc (MGNX) This Quarter
www.americanbankingnews.com - December 22 at 6:22 PM
MacroGenics Inc (MGNX) Receives Average Recommendation of "Buy" from AnalystsMacroGenics Inc (MGNX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 21 at 3:54 PM
MacroGenics (MGNX) Rating Lowered to Strong Sell at BidaskClubMacroGenics (MGNX) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 17 at 12:50 AM
MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : December 14, 2017MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : December 14, 2017
finance.yahoo.com - December 14 at 6:07 PM
Macrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASHMacrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASH
www.streetinsider.com - December 13 at 5:45 PM
Macrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASH - StreetInsider.comMacrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASH - StreetInsider.com
www.streetinsider.com - December 13 at 9:28 AM
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : December 13, 2017MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : December 13, 2017
finance.yahoo.com - December 13 at 9:28 AM
MacroGenics (MGNX) Earns "Buy" Rating from Raymond James FinancialMacroGenics (MGNX) Earns "Buy" Rating from Raymond James Financial
www.americanbankingnews.com - December 12 at 9:28 AM
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH MeetingPhase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
finance.yahoo.com - December 11 at 5:48 PM
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with IncyteMacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
finance.yahoo.com - December 5 at 5:30 PM
MacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $152.60 MillionMacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $152.60 Million
www.americanbankingnews.com - December 4 at 10:12 AM
MacroGenics (MGNX) Upgraded by ValuEngine to "Sell"MacroGenics (MGNX) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 7:30 AM
Zacks: Analysts Expect MacroGenics, Inc. (MGNX) to Post $2.58 EPSZacks: Analysts Expect MacroGenics, Inc. (MGNX) to Post $2.58 EPS
www.americanbankingnews.com - December 2 at 1:38 PM
MacroGenics, Inc. (MGNX) Given Average Recommendation of "Buy" by BrokeragesMacroGenics, Inc. (MGNX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 26 at 4:08 PM
MacroGenics, Inc. (MGNX) Downgraded to "Strong Sell" at ValuEngineMacroGenics, Inc. (MGNX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - November 26 at 12:56 PM
MacroGenics, Inc. (MGNX) SVP Jon Marc Wigginton Sells 5,000 SharesMacroGenics, Inc. (MGNX) SVP Jon Marc Wigginton Sells 5,000 Shares
www.americanbankingnews.com - November 21 at 9:08 PM

SEC Filings

MacroGenics (NASDAQ:MGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MacroGenics (NASDAQ:MGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MacroGenics (NASDAQ MGNX) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.